Call for Letters of Intent: Research Initiative 2014 – April 28 deadline
We’re now accepting Letters of Intent for our 2014 Research Initiative!
Did you know that several of our esteemed researchers got their start from National MPS Society research grants? Researchers: read more for submission details.
First Treatment for MPS IVA Approved
BioMarin Pharmaceutical announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Vimizim™ (elosulfase alfa), the first specific therapy approved for the treatment of Morquio A (MPS IVA syndrome.)
40 Years of Achievements Gala Invitation
The National MPS Society cordially invites you to join us in celebrating 40 years of achievements through honoring the heroes of MPS research, innovation, advocacy, and courage.
27th Annual Family Conference Photos!
Thank you to everyone that attended our 27th Annual Family Conference in San Antonio, TX. Photos from the conference are available on our Facebook page.
Mucopolysaccharidoses (MPS) and related diseases are genetic lysosomal storage diseases (LSD) caused by the body's inability to produce specific enzymes. Normally, the body uses enzymes to break down and recycle materials in cells. In individuals with MPS and related diseases, the missing or insufficient enzyme prevents the proper recycling process, resulting in the storage of materials in virtually every cell of the body.